Close menu




June 19th, 2025 | 07:05 CEST

Share price speculation thanks to drones and artificial intelligence: Rheinmetall, BioNTech, and NetraMark shares

  • Biotechnology
  • AI
  • Defense
  • Drones
Photo credits: Anduril Industries

Drones and artificial intelligence are set to revolutionize entire industries. Listed companies that play a leading role in this transformation hold significant upside potential, such as NetraMark. Using artificial intelligence, the Company helps pharmaceutical and biotech companies shorten development times and reduce costs. NetraMark also aims to help shape industry trends. BioNTech, too, relies on AI for its research, frequently acquiring specialized companies. Perhaps NetraMark will be next? In any case, the Canadians would still be a bargain. Rheinmetall shares, on the other hand, are certainly not cheap. However, the multibillion-euro defense budgets for rearmament in Europe are fueling speculation. In order to be able to deliver not only tanks, howitzers, and ammunition quickly, but also cutting-edge technology, Germany's largest defense contractor is focusing on partnerships. This is evident in its latest partnership, which is expected to enable Rheinmetall to deliver combat and kamikaze drones quickly.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: RHEINMETALL AG | DE0007030009 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , NETRAMARK HOLDINGS INC | CA64119M1059

Table of contents:


    NetraMark Holdings: Low-cost AI specialist with takeover potential

    NetraMark Holdings is positioning itself at the interface between the pharmaceutical industry and artificial intelligence – aiming to make clinical trials more efficient, precise, and compliant with regulations through AI-supported analytics.

    A new scientific publication in the Journal of the Society for Clinical Data Management (JSCDM) shows that the technology company is well on its way to establishing itself as one of the designers of the next generation of clinical trials. The lead author of "Current Opportunities for the Integration and Use of AI/ML in Clinical Trials: Perspectives on Good Clinical Practice" is Dr. Joseph Geraci, Founder and Chief Scientific Officer of NetraMark. The publication is based on collaboration with renowned representatives of leading pharmaceutical companies and health authorities, including Pfizer, Sanofi, the FDA (US), EMA (EU), and technology companies such as Cognizant and Saama Technologies. The common message: Artificial intelligence and machine learning (ML) have the potential to improve data quality and patient outcomes in clinical research significantly.

    Specifically, the paper examines seven practical use cases where AI has been shown to deliver benefits in terms of transparency, safety, efficiency, and accuracy in clinical trials. The scenarios range from patient stratification and data validation to the prediction of treatment outcomes.

    Of course, NetraAI is also mentioned. AI is at the heart of NetraMark's technology platform, which is specifically designed to address the challenges of small, fragmented, or difficult-to-interpret data sets - a common problem in early clinical phases or for rare diseases. The platform enables pharmaceutical companies to identify potential patient groups more accurately, detect anomalies at an early stage, and optimize clinical designs – all while taking regulatory requirements into account. NetraMark has already gained an important partner for the market penetration of NetraAI in the current year. The contract research organization Worldwide Clinical Trials (Worldwide) offers its customers the NetraAI platform to optimize studies, achieve shorter timelines, lower costs, and ultimately achieve higher success rates.

    NetraMark shares have been trading sideways since February. The Company is currently valued at around CAD 100 million for its AI business. This is unlikely to remain the case for long.

    https://youtu.be/asqAzE7_2-M?si=7gsnEPeZxIm5VI4s

    BioNTech focuses on AI

    Could NetraMark be a takeover candidate for BioNTech? Perhaps. What is certain is that the Mainz-based company has been using its billions in revenue from the COVID-19 vaccine for several years to establish itself as a pioneer in the field of artificial intelligence (AI) in drug research.

    BioNTech primarily uses AI to identify new targets, predict drug candidates, and individualize cancer therapies. In personalized oncology - a core focus of the Company - AI enables the rapid analysis of large amounts of data from individual patient tumor profiles. The goal is to develop customized mRNA-based therapies that mobilize the immune system to target cancer cells. According to the Company, AI can reduce the time needed to identify potential mRNA candidates from several months to a few days or weeks. BioNTech can also respond more quickly to new pathogens – a decisive advantage in pandemic situations or with rapidly mutating cancers.

    In order to systematically expand its AI expertise, BioNTech has made targeted acquisitions of companies in the field of artificial intelligence in recent years. Probably the most important AI acquisition to date was the takeover of the British start-up InstaDeep for around GBP 500 million in 2023. InstaDeep specializes in deep reinforcement learning and bioinformatics. The Company's AI models help solve complex biological problems like protein structure prediction, vaccine design, and drug screening. Since the acquisition, InstaDeep has been an integral part of the research platform as BioNTech AI Solutions.

    BioNTech has announced that it will continue to actively pursue acquisitions in the AI sector. This will primarily focus on areas such as generative AI for molecular design, image analysis in pathology, and multi-omics data integration.

    Rheinmetall: Drones for Europe

    Rheinmetall is also focusing on high-tech. Although Germany's largest defense contractor is best known for its tanks, howitzers, and ammunition, it is continuing to expand its portfolio, particularly in the technology sector. Yesterday, it attracted attention with a strategic partnership in the drone sector. Rheinmetall plans to work with US technology company Anduril Industries to jointly develop and manufacture various software-defined autonomous systems.

    Among other things, the partnership will focus on European variants of Anduril's Barracuda drone and Fury kamikaze drone, as well as their integration into Rheinmetall's Battlesuite digital platform for networked military systems. In addition, opportunities in the European market for solid-propellant rocket engines will be explored.

    Anduril CEO Brian Schimpf commented: "Together with Rheinmetall, we are developing systems that can be produced quickly, deployed widely, and adapted to changing NATO missions."

    This shows once again that Rheinmetall is increasingly focusing on cooperation in order to rapidly expand its product portfolio and deliver quickly. At the end of April, for example, an agreement was reached with Lockheed Martin to manufacture ATACMS missiles and parts for the F-35 fighter jet in Europe. There are also plans to establish a European center of excellence for rockets and missiles.


    AI has the potential to revolutionize drug research. NetraMark is an exciting AI stock with catch-up potential. It will also likely become an increasingly attractive takeover target, perhaps for BioNTech. The Mainz-based company is also strongly committed to AI. Rheinmetall also wants to play a role in future technologies. To deliver quickly, it is entering into partnerships, which should pay off.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Carsten Mainitz on November 19th, 2026 | 05:20 CET

    Uranium and Reactor Technology: Standard Uranium, Cameco and SGL Carbon – Who Benefits Most from the Nuclear Comeback?

    • Uranium
    • Nuclear power
    • Nuclear energy
    • Reactors
    • Reactor technology
    • AI
    • Supply chains

    Nuclear power needs fresh supplies! Longer operating lifetimes, new reactors and power-hungry data centres are strengthening demand and fuelling optimism for the industry. Geopolitical tensions are pushing operators to secure supplies, while additional supply requires substantial capital and time. For investors, this opens up opportunities along the entire nuclear value chain. Standard Uranium starts at the very beginning, exploring for new deposits in Canada's Athabasca region. Cameco already generates revenue from uranium and fuel services and is also involved in reactor technology through Westinghouse. SGL Carbon, in turn, supplies speciality graphite for X-energy's reactors and recently secured another order worth around USD 90 million. Which company will take off now?

    Read

    Commented by Jens Castner on November 18th, 2026 | 05:40 CET

    Treasures from the depths, a slump in the stock market: Lynas, Almonty and Cameco tempt with low share prices

    • Critical raw materials
    • Rare earths
    • Tungsten
    • Uranium
    • Almonty Industries
    • Cameco
    • AI
    • Lynas Rare Earths

    Without rare earths, no electric motors; without tungsten, no defence industry; without uranium, no nuclear power. The West needs these raw materials more urgently than ever and depends on a handful of suppliers that mine in politically stable countries. Yet shares in Lynas Rare Earths, Almonty Industries and Cameco are falling as if there were no shortage – down by one-third to two-thirds from their highs for the year. We have taken a close look at the three producers following their latest quarterly results. One of the shares has reached bargain levels.

    Read